REIN THERAPEUTICS INC (RNTX) Stock News

USA - Nasdaq - NASDAQ:RNTX - US00887A2042 - Common Stock

1.48 USD

+0.02 (+1.37%)

Last: 11/26/2025, 9:49:45 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

RNTX Latest News, Press Relases and Analysis

All

Press Releases

20 days ago - By: Rein Therapeutics

Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF

22 days ago - By: Benzinga - Mentions: SRPT CMPS EVOK QURE ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

23 days ago - By: Benzinga - Mentions: EXAS SNDX SRPT MCRB ...

12 Health Care Stocks Moving In Monday's After-Market Session

23 days ago - By: Rein Therapeutics

Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

2 months ago - By: Rein Therapeutics

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

2 months ago - By: Rein Therapeutics

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis

3 months ago - By: Yahoo Finance - Mentions: PANW CAT UBS CCI ...

Palo Alto upgraded, Li Auto downgraded: Wall Street's top analyst calls

3 months ago - By: Rein Therapeutics

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

3 months ago - By: Rein Therapeutics

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

5 months ago - By: Rein Therapeutics, Inc.

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

6 months ago - By: Rein Therapeutics, Inc. - Mentions: IQV

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

6 months ago - By: Rein Therapeutics, Inc.

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

6 months ago - By: Rein Therapeutics, Inc.

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

7 months ago - By: Rein Therapeutics, Inc.

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

7 months ago - By: Rein Therapeutics, Inc.

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

7 months ago - By: Rein Therapeutics, Inc.

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

7 months ago - By: Rein Therapeutics, Inc.

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

7 months ago - By: Rein Therapeutics, Inc.

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

8 months ago - By: Rein Therapeutics, Inc.

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

8 months ago - By: Rein Therapeutics, Inc.

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

11 months ago - By: Rein Therapeutics, Inc. - Mentions: ALRN

Aileron Therapeutics Announces Rebranding to Rein Therapeutics

4 years ago - By: StockMarket.com - Mentions: PFE BNTX MRNA ADGI ...

Top Health Care Stocks To Buy In September 2021? 4 To Watch